Ginseng

True ginsengs are Panax (Araliaceae): shade herbs of temperate forests with palmate compound leaves, an umbel of small flowers, and red berries. The medicinal part is the aged root, often with a “neck” of rhizome scars that records winters. NCBI Taxonomy: P. ginseng 4054, P. quinquefolius 44588, P. notoginseng 44586, P. japonicus 44685. Eleutherococcus senticosus is 82096—same family, different genus.

Asian ginseng (P. ginseng C.A. Mey.) is native to Korea, northeastern China, and the Russian Far East. Cultivation is now the crop; wild stock is scarce. White ginseng is the peeled, sun- or oven-dried root. Red ginseng is steamed, then dried: same species, a Maillard-and-saponin transformation. EMA and the Ph. Eur. (Ginseng radix, monograph 1523) cover both, requiring a minimum sum of ginsenosides Rg1 and Rb1. Korean, Chinese, and “Manchurian” on a label are geography and process, not three botanies.

American ginseng (P. quinquefolius L.) is native to eastern North American hardwoods. Wild plants are slow and still listed under CITES Appendix II; the U.S. Fish and Wildlife Service regulates export. Wisconsin, Ontario, and British Columbia grow the cultivated crop that supplies most capsules and much of the root shipped to China. In Chinese pharmacy this species is xī yáng shēn, a cooler “yin” root, not a substitute for rénshēn. The leaflets and berry look like Asian ginseng to a casual eye; the chemistry does not.

Notoginseng (P. notoginseng (Burkill) F.H. Chen; sānqī, tienchi) is a southwestern Chinese species used for trauma, bleeding, and “moving blood.” It carries notoginsenoside R1 in addition to familiar ginsenosides. It is the lead herb in the proprietary mix Yunnan Baiyao. That is a hemostatic tradition, not the fatigue monograph. Japanese ginseng (P. japonicus) leans on rhizome and oleanane-type saponins (chikusetsusaponins) more than the classic Korean taproot profile. Vietnamese ginseng (P. vietnamensis) is another true Panax with its own saponins; it is not the Wisconsin or G115 product.

Eleuthero is the lookalike that causes the most confusion. E. senticosus (ci wu jia, Siberian ginseng) has eleutherosides, not ginsenosides. MSKCC files it separately and notes it is not Asian, American, or notoginseng. LiverTox explains that the word ginseng covers eleven Panax species, plus this naming tangle. Quality surveys find products with little or no ginsenoside, so confirming identity is the first step.

Chinese materia medica treated rénshēn as a rare forest tonic for centuries: qi, collapse, recovery. The man-shaped root became a luxury good. Korea built a steamed red-ginseng state industry. Japan used P. japonicus as a local stand-in. None of that was a randomized trial, and none of it licensed every plant later sold as ginseng.

American ginseng entered Qing-era trade as a cooler counterpart. Nineteenth-century North American wild-digging emptied woods; CITES listing in 1975 is the hangover. Cultivated Wisconsin root became the export that China still buys. That trade is why a Mayo-led cancer-fatigue trial could specify “Wisconsin ginseng” as a defined chemotype.

Twentieth-century phytomedicine isolated ginsenosides, standardized G115 and similar extracts, and popularized “adaptogen” as a product category. Soviet research on eleuthero as a cheaper tonic is why health-food shelves still say Siberian ginseng. EMA’s HMPC later wrote a traditional-use monograph for P. ginseng radix (asthenia, fatigue, weakness)—not well-established like horse-chestnut seed, and not a license for American or Siberian products.

The modern clinical picture is split by species: Asian extracts for some erectile-dysfunction and glycemic work of uneven quality; American root for cancer-related fatigue (Barton N07C2) and a documented warfarin interaction (Yuan 2004); notoginseng in trauma formulas. Much of ginseng’s history is a story of labels moving faster than botany.

The active story is ginsenosides: dammarane triterpene saponins. They split into protopanaxadiol (PPD) types—Rb1, Rb2, Rc, Rd, Rg3—and protopanaxatriol (PPT) types—Re, Rg1, Rg2, Rh1. Fresh P. ginseng is dominated by Rb1, Rb2, Rc, Re, and Rg1. Gut bacteria deglycosylate them toward compound K, which is why two people can swallow the same capsule and not share a metabolite profile.

Species differ by ratio, not by a unique magic molecule. American root is often richer in Rb1 relative to Rg1 and is traditionally read as less “stimulating.” Asian root, especially some Korean chemovars, can be relatively higher in Rg1. Red processing of P. ginseng further rewrites the mix: steaming drops some native glycosides and generates or enriches rarer ones (Rg3, Rk1, Rg5, Rh4). He, Huang, and colleagues (Planta Medica 2018) review that white-versus-red gap as chemistry plus immunomodulation, not as two plants. Notoginseng adds notoginsenoside R1 and a hemostatic/antiplatelet literature that does not copy onto a Korean red-ginseng tea.

Eleutherosides in E. senticosus are lignans and phenylpropanoids. They are not ginsenosides. Calling eleuthero “Siberian ginseng” is like calling maca Peruvian ginseng: a trade name, not a botanical relationship.

Mechanisms proposed in reviews (Mancuso and Santangelo, 2020; MSKCC) include mixed CNS stimulation and sedation depending on the ginsenoside, nitric-oxide effects in endothelium and corpus cavernosum, immune modulation, and glucose handling. Those are promising experimental leads. They do not mean every energy drink works like a studied G115 extract.

Asian ginseng (P. ginseng). EMA traditional use is symptomatic asthenia—fatigue and weakness—for specified white and red root preparations, on long-standing use rather than a decisive modern RCT stack. NCCIH (Asian ginseng page): short-term oral use up to about six months in usual amounts looks acceptable for many adults; evidence for the big claims (performance, immunity, “adaptogen”) is mixed. A 2021 Cochrane review of ginseng for erectile dysfunction found a possible small effect with low-certainty evidence. A 2022 Nutrients meta-analysis (Naseri et al.) pooled 20 randomized trials in prediabetes and type 2 diabetes and found that ginseng significantly lowered fasting blood glucose and HOMA-IR, a measure of insulin resistance; the trials mixed species and products, so more species-specific research would help. MSKCC: human data limited; do not confuse this plant with American, Siberian, or notoginseng.

American ginseng (P. quinquefolius). The most encouraging clinical result is for cancer-related fatigue: Barton and colleagues’ Alliance/NCCTG N07C2 trial (JNCI 2013; PMC3888141) randomized 2,000 mg/day of Wisconsin American ginseng versus placebo for eight weeks and saw fatigue improve, especially in people still on cancer therapy. That is ground American root, not an ethanol extract Barton flagged as a phytoestrogen concern in breast-cancer patients. COLD-fX / CVT-E002 (McElhaney 2006) is a specific American-ginseng extract studied for respiratory symptoms—not a license for every cold capsule. Glucose-lowering work exists; so does the warfarin trial below. TCM uses this species as a yin tonic, which is a tradition, not a lab result.

Notoginseng (P. notoginseng). Trauma, bleeding, “stasis”—and Yunnan Baiyao as a multi-herb product with sanqi as the named core (MSKCC). Do not take a hemostatic tradition and a fatigue capsule as interchangeable. Raw versus steamed notoginseng even differ in antiplatelet comparisons in the ethnopharmacology literature. It is a different product from Korean red ginseng.

Eleuthero. Traditional adaptogen with a history of Soviet performance research. Different chemistry. MSKCC: not Panax; watch digoxin because of assay/interference history. Do not use it to “get the same ginseng” cheaper.

Do not use any of these to replace cancer treatment, to self-treat hypoglycemia, or as a daily stimulant on top of energy drinks. Evidence for athletic performance is still limited. Each species has its own evidence, so it helps to match the trial to the product rather than summing everything up as “ginseng works.”

White Asian: dried P. ginseng root, teas, powders, hydroalcoholic extracts. EMA lists comminuted root decoctions, powdered root (roughly 600–2,000 mg/day in the monograph’s traditional posology), and several dry/soft/liquid extracts, including a 4% total-ginsenoside dry extract related to the old G115-type products.

Red Asian: steamed then dried P. ginseng. Korean red ginseng extracts are a separate commercial chemotype. He 2018 is the processing paper, not a dose chart.

American: dried root powder (the Barton 2 g/day design), extracts, and proprietary polysaccharide-rich fractions (CVT-E002). Wild root is a conservation object; cultivated Wisconsin/Ontario root is the supplement crop. Prefer products that name Panax quinquefolius and a ginsenoside method. Ethanol-processed products are not the N07C2 powder.

Notoginseng: root slices, powders, and formulas such as Yunnan Baiyao. That formula is proprietary and not a single-herb dose. Eleuthero: root/rhizome as “Siberian ginseng”—read the Latin. If a label cannot say Panax ginseng, P. quinquefolius, P. notoginseng, or Eleutherococcus senticosus, it is best treated as a blend of uncertain identity.